Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][5][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false and misleading statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Participation - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member, with no impact on their ability to share in any recovery [7]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [8].

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In WPP To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in WPP between February 27, 2025 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 21, 2 ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [1][3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and failed to disclose adverse facts affecting its financial outlook [3]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of services, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [3]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter results, reporting adjusted earnings of approximately $5.50 per share, which was below expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance for full-year adjusted earnings to no less than $19.00 per diluted share, a 13.6% reduction [5]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Stride, Inc. for alleged violations of federal securities laws, particularly regarding misleading statements about the company's products and services, which have led to significant investor losses [1][3]. Group 1: Allegations Against Stride - The complaint alleges that Stride and its executives made false and misleading statements about the company's offerings to educational institutions, while inflating enrollment numbers and cutting staff costs beyond legal limits [3]. - A report from Gallup-McKinley County Schools Board of Education accused Stride of fraud and deceptive practices, including retaining "ghost students" to secure state funding and ignoring compliance requirements [4]. Group 2: Stock Price Impact - Following the allegations, Stride's stock price dropped by $18.60, or 11.7%, closing at $139.76 per share on September 15, 2025, causing harm to investors [5]. - After Stride's announcement of limited enrollment growth and operational issues, the stock price fell as much as 51% during intraday trading on October 29, 2025, further injuring investors [6]. Group 3: Legal Proceedings - Investors who suffered losses during the specified period are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of January 12, 2026, to seek the role of lead plaintiff in the class action [1][7].

加州爾灣, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 發展迅速的半導體及國防科技公司 Mobix Labs, Inc.（NASDAQ: MOBX）（「Mobix」）今天宣布，已向特拉華州衡平法院（Delaware Court of Chancery）提交經核實的起訴狀，指控 Tik Yang Tse（又名 Denis Tse）、ACE Equity Partners International、Asia-IO Equity Partners International 和 ACE SO4 Holdings Limited 涉及欺詐行為、故意作出不實陳述，以及違反對 ACE 具有約束力的投資義務契約。 經核實的起訴狀指稱，是次訴訟「源於被告 ACE 未能履行注資義務，按契約協定提供 3,000 萬美元的融資」，該項融資與 Mobix 於 2023 年進行的業務合併有關。 起訴狀指出，「ACE 從未按照認購協議的規定，提供所需的 3,000 萬美元融資。」 起訴狀對 Denis Tse 提出了具體指控，聲稱他「親身參與了本案中所指控的談判及不實陳述」，並且「明知故犯，蓄意以虛假方式誘使原 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The financial and legal pressures on aTyr Pharma, Inc. (NASDAQ: ATYR) intensified earlier this month as the clinical-stage biotech company reported third-quarter results on Nov. 6 that missed Wall Street estimates, all while navigating high-stakes securities class action litigation. Global plaintiffs’ rights firm Hagens Berman has been investigating the alleged claims. The firm urges investors in aTyr who suffered significant losses to submit your losses now. ...

Core Insights - Holzer & Holzer, LLC is investigating Bitdeer Technologies Group for potential compliance issues with federal securities laws following a significant delay in the development of its second-generation SEAL04 chip, which was announced in the company's third-quarter financial results [1] - The announcement of the delay led to a drop in Bitdeer's stock price [1] Company Financials - Bitdeer reported its unaudited financial results for the third quarter ended September 30, 2025 [1] - The company indicated that the development of its SEAL04 chip is "significantly delayed" [1] Legal Context - Investors who purchased Bitdeer stock and experienced losses are encouraged to contact Holzer & Holzer for legal assistance [2] - Holzer & Holzer is recognized as a top-rated securities litigation law firm and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Points - A class action securities lawsuit has been filed against Stride, Inc. to recover losses for shareholders affected by alleged securities fraud between October 22, 2024, and October 28, 2025 [2] - The lawsuit claims that Stride engaged in various fraudulent activities, including inflating enrollment numbers, cutting staffing costs, ignoring compliance requirements, suppressing whistleblowers, and losing enrollments [3] Company Details - Stride, Inc. is facing serious allegations of misconduct that could impact its reputation and financial standing [3] - The lawsuit highlights significant operational issues within Stride, including the retention of "ghost students" and non-compliance with educational regulations [3] Legal Proceedings - Shareholders who suffered losses during the specified time frame are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [4] - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this case, emphasizing their extensive experience and success in similar cases [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated due to misleading statements regarding the New Drug Application (NDA) for aficamten, which may have led to significant investor losses [2][5][7]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Cytokinetics between December 27, 2023, and May 6, 2025, to discuss their legal rights [1][2]. - There is a deadline of November 17, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [2]. Group 2: Misleading Statements - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, expecting FDA approval in the second half of 2025 [5]. - The company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [5][6]. Group 3: Impact on Investors - Following the revelation of the misleading statements, class members purchased Cytokinetics' common stock at inflated prices and subsequently suffered significant losses [7]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members [8].